What it means to be a caregiver

When you are a caregiver, you do more than just care

You can make a difference in how your partner, family member, or friend deals with cancer. Giving emotional and practical support to the person you care for may take many forms. It helps to:

Be informed. Explore this website with your loved one to best understand the journey ahead and what to expect from this treatment. For more information, please see the BRAFTOVI Medication Guide and the MEKTOVI Patient Information.

Understand your role. This website offers information about BRAFTOVI + MEKTOVI, what your loved one who’s taking it can expect during treatment, as well as other helpful resources. Keep in mind, your support is also a part of their treatment. There are many ways to be there for someone. Find out what works best for you and do not be afraid to ask for help from others.

Know you don’t have to have cancer to fight cancer. Talk to the person you care for. Let them know how you are going to help. Remember that open communication is important.


As a caregiver, looking after your own well-being isn’t selfish, it’s necessary

Your role as a caregiver can be a valuable experience. It can also be physically and emotionally draining. Caregivers are often so busy focusing on their partner, family member, or friend that they put their own needs and feelings aside.

You may want to consider the following helpful tips to keep yourself from feeling overwhelmed:

CareGiver_Tips_R1

Meet Anne, a caregiver to a patient on BRAFTOVI + MEKTOVI

Scroll down to learn more about the Tovi2 patient and caregiver text message support programs. The makers of BRAFTOVI + MEKTOVI are committed to supporting not only patients but also caregivers in their battle against a certain type* of BRAF+ metastatic melanoma.

CAREGIVER TEXT MESSAGE PROGRAM

*BRAF V600E or V600K mutation.

Caregivers need support, too

Caregivers play an important, often demanding, role. That’s why we offer a separate program just for caregivers.

Sign up for the caregiver text message support program

1.On your mobile phone, text the word Tovi2 (or Tovi2care for caregivers) to 99181.

2. When you get a message back from us, text back AGREE to confirm your participation in the support program.

3. Then answer 3 questions:

Your name so we can personalize your messages
Your ZIP code so we can set your time zone
The date you (or your loved one) started or plan to start taking BRAFTOVI + MEKTOVI

In your text message program, enter '99181' in the 'To:' field and type the word 'Tovi2' in the 'Text Message' field, and then send message to sign up for the Tovi2 text message support program
Lightbulb icon

To set your preferences, just text MENU for a list of options.

In your text message program, enter '99181' in the 'To:' field and type the word 'Tovi2' in the 'Text Message' field, and then send message to sign up for the Tovi2 text message support program

*BRAFTOVI + MEKTOVI text message support program. By texting Tovi2 to 99181, you consent to receive autodialed marketing and other texts from Pfizer and its service providers regarding the BRAFTOVI + MEKTOVI text message support program at the phone number provided. You understand that providing this consent is not required or a condition of purchasing any products or services. Number of messages depends on your selections. Up to 8 messages per week in the first 6 weeks and up to 2 per week, thereafter, unless you request more than this. Message and data rates may apply. Complete terms can be found at https://mhm.carespeak.com/array/terms.html and Pfizer’s privacy policy at https://www.pfizer.com/privacy. Text STOP to 99181 to opt-out.

Explore our caregiver text message support program for BRAFTOVI + MEKTOVI

Remember, this website is being provided for your information only and does not replace the medical advice of your healthcare provider.

Be sure to consult your healthcare provider regarding any questions or concerns you may have about your specific medical condition or treatment plan.

You are not in this alone

No one fights alone image

There are resources geared toward supporting caregivers through their loved ones' cancer diagnosis and treatment. Here are just a few:

Pfizer does not control or endorse third-party organizations. The information provided by Pfizer or these organizations is meant for informational purposes only. It is not meant to replace your doctor's medical advice.

Important Safety
Information and Indication

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about BRAFTOVI and MEKTOVI?

BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) may cause serious side effects, including:

  • Risk of new skin cancers. BRAFTOVI, when used alone or with MEKTOVI, may cause skin cancers called cutaneous squamous cell carcinoma or basal cell carcinoma. Talk to your healthcare provider about your risk for these cancers.

    Check your skin and tell your healthcare provider right away about any skin changes, including a:

    • new wart
    • skin sore or reddish bump that bleeds or does not heal
    • change in size or color of a mole

    Your healthcare provider should check your skin before and every 2 months during treatment, and for up to 6 months after you stop treatment to look for any new skin cancers.

    Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that develop during treatment.

  • Heart problems, including heart failure. Your healthcare provider should check your heart function before and during treatment with MEKTOVI. Call your healthcare provider right away if you have any of the following signs and symptoms of a heart problem:
    • feeling like your heart is pounding or racing
    • shortness of breath
    • swelling of your ankles and feet
    • feeling light-­headed
  • Blood clots. MEKTOVI can cause blood clots in your arms or legs, which can travel to your lungs and can lead to death. Get medical help right away if you have the following symptoms:
    • chest pain
    • sudden shortness of breath or trouble breathing
    • pain in your legs with or without swelling
    • swelling in your arms and legs
    • a cool, pale arm or leg
  • Bleeding problems. BRAFTOVI, when taken with MEKTOVI, can cause serious bleeding problems, including in your stomach or brain, that can lead to death. Call your healthcare provider and get medical help right away if you have any signs of bleeding, including:
    • headaches, dizziness, or feeling weak
    • cough up blood or blood clots
    • vomit blood or your vomit looks like “coffee grounds”
    • red or black stools that look like tar
  • Eye problems. MEKTOVI can cause serious eye problems that might lead to blindness. Call your healthcare provider right away if you develop any of these symptoms of eye problems:
    • blurred vision, loss of vision, or other vision changes
    • see colored dots
    • see halos (blurred outline around objects)
    • eye pain, swelling, or redness
  • Lung or breathing problems. MEKTOVI can cause lung or breathing problems. Tell your healthcare provider if you have any new or worsening symptoms of lung or breathing problems, including:
    • shortness of breath
    • cough
  • Liver problems. Your healthcare provider should perform blood tests to check your liver function before and during treatment with MEKTOVI. Tell your healthcare provider if you have any of the following signs and symptoms of a liver problem:
    • yellowing of your skin or the white part of your eyes (jaundice)
    • dark or brown (tea­-colored) urine
    • nausea or vomiting
    • loss of appetite
  • Muscle problems (rhabdomyolysis). MEKTOVI can cause muscle problems that can be severe. MEKTOVI may increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Your healthcare provider should perform a blood test to check your CPK levels before and during treatment. Tell your healthcare provider right away if you develop any of these symptoms:
    • weakness
    • muscle aches or pain
    • dark, reddish urine
  • Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider should do tests before you start taking BRAFTOVI with MEKTOVI and during your treatment to check your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, light-­headed, dizzy, or if you feel your heart beating irregularly or fast while taking BRAFTOVI with MEKTOVI. These symptoms may be related to QT prolongation.

Tell your healthcare team if you are pregnant or plan to become pregnant. BRAFTOVI and MEKTOVI can harm your unborn baby. Females who are able to become pregnant should use effective non-hormonal birth control (contraception) during and for at least:

    • 2 weeks after the last dose of BRAFTOVI
    • 30 days after the last dose of MEKTOVI
    • Birth control methods that contain hormones (such as birth control pills, injections, or transdermal systems) may not work as well during treatment with BRAFTOVI.
    • Your healthcare team will do a pregnancy test before you start taking BRAFTOVI and MEKTOVI. Tell your healthcare provider right away if you become pregnant or think you might become pregnant during treatment.

Talk to your healthcare team if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment with BRAFTOVI and MEKTOVI and for:

    • 2 weeks after the final dose of BRAFTOVI
    • 3 days after the final dose of MEKTOVI

BRAFTOVI may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you.

The most common side effects of BRAFTOVI when taken with MEKTOVI, include: fatigue, nausea, diarrhea, vomiting, abdominal pain, and pain or swelling of your joints.

Before taking BRAFTOVI + MEKTOVI, tell your healthcare provider about all of your medical conditions, including if you:

  • have had bleeding problems
  • have eye problems
  • have heart problems, including a condition called long QT syndrome
  • have been told that you have low blood levels of potassium, calcium, or magnesium
  • have liver or kidney problems
  • have had blood clots
  • have lung or breathing problems
  • have any muscle problems
  • have high blood pressure (hypertension)
  • are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over­-the­-counter medicines, vitamins, and herbal supplements. BRAFTOVI and certain other medicines can affect each other, causing side effects or affecting how BRAFTOVI or other medicines work. You should also avoid grapefruit products during treatment with BRAFTOVI.

These are not all the possible side effects of BRAFTOVI and MEKTOVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects related to BRAFTOVI + MEKTOVI products at 1-800-438-1985.

Please see both BRAFTOVI full Prescribing Information, including Medication Guide, and MEKTOVI full Prescribing Information, including Patient Information for additional information.

What is BRAFTOVI + MEKTOVI?

BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) are prescription medicines used together to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body or cannot be removed by surgery, and
  • that has a certain type of abnormal “BRAF” gene

BRAFTOVI should not be used to treat people with wild­type BRAF melanoma. Your healthcare provider will perform a test to make sure that BRAFTOVI + MEKTOVI is right for you.

It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.

Important Safety
Information and Indication

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about BRAFTOVI and MEKTOVI?

BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) may cause serious side effects, including:

  • Risk of new skin cancers. BRAFTOVI, when used alone or with MEKTOVI, may cause skin cancers called cutaneous squamous cell carcinoma or basal cell carcinoma. Talk to your healthcare provider about your risk for these cancers.

    Check your skin and tell your healthcare provider right away about any skin changes, including a:

    • new wart
    • skin sore or reddish bump that bleeds or does not heal
    • change in size or color of a mole

    Your healthcare provider should check your skin before and every 2 months during treatment, and for up to 6 months after you stop treatment to look for any new skin cancers.

    Your healthcare provider should also check for cancers that may not occur on the skin. Tell your healthcare provider about any new symptoms that develop during treatment.

  • Heart problems, including heart failure. Your healthcare provider should check your heart function before and during treatment with MEKTOVI. Call your healthcare provider right away if you have any of the following signs and symptoms of a heart problem:
    • feeling like your heart is pounding or racing
    • shortness of breath
    • swelling of your ankles and feet
    • feeling light-­headed
  • Blood clots. MEKTOVI can cause blood clots in your arms or legs, which can travel to your lungs and can lead to death. Get medical help right away if you have the following symptoms:
    • chest pain
    • sudden shortness of breath or trouble breathing
    • pain in your legs with or without swelling
    • swelling in your arms and legs
    • a cool, pale arm or leg
  • Bleeding problems. BRAFTOVI, when taken with MEKTOVI, can cause serious bleeding problems, including in your stomach or brain, that can lead to death. Call your healthcare provider and get medical help right away if you have any signs of bleeding, including:
    • headaches, dizziness, or feeling weak
    • cough up blood or blood clots
    • vomit blood or your vomit looks like “coffee grounds”
    • red or black stools that look like tar
  • Eye problems. MEKTOVI can cause serious eye problems that might lead to blindness. Call your healthcare provider right away if you develop any of these symptoms of eye problems:
    • blurred vision, loss of vision, or other vision changes
    • see colored dots
    • see halos (blurred outline around objects)
    • eye pain, swelling, or redness
  • Lung or breathing problems. MEKTOVI can cause lung or breathing problems. Tell your healthcare provider if you have any new or worsening symptoms of lung or breathing problems, including:
    • shortness of breath
    • cough
  • Liver problems. Your healthcare provider should perform blood tests to check your liver function before and during treatment with MEKTOVI. Tell your healthcare provider if you have any of the following signs and symptoms of a liver problem:
    • yellowing of your skin or the white part of your eyes (jaundice)
    • dark or brown (tea­-colored) urine
    • nausea or vomiting
    • loss of appetite
  • Muscle problems (rhabdomyolysis). MEKTOVI can cause muscle problems that can be severe. MEKTOVI may increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Your healthcare provider should perform a blood test to check your CPK levels before and during treatment. Tell your healthcare provider right away if you develop any of these symptoms:
    • weakness
    • muscle aches or pain
    • dark, reddish urine
  • Changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heartbeats that can be life-threatening. Your healthcare provider should do tests before you start taking BRAFTOVI with MEKTOVI and during your treatment to check your body salts (electrolytes). Tell your healthcare provider right away if you feel faint, light-­headed, dizzy, or if you feel your heart beating irregularly or fast while taking BRAFTOVI with MEKTOVI. These symptoms may be related to QT prolongation.

Tell your healthcare team if you are pregnant or plan to become pregnant. BRAFTOVI and MEKTOVI can harm your unborn baby. Females who are able to become pregnant should use effective non-hormonal birth control (contraception) during and for at least:

    • 2 weeks after the last dose of BRAFTOVI
    • 30 days after the last dose of MEKTOVI
    • Birth control methods that contain hormones (such as birth control pills, injections, or transdermal systems) may not work as well during treatment with BRAFTOVI.
    • Your healthcare team will do a pregnancy test before you start taking BRAFTOVI and MEKTOVI. Tell your healthcare provider right away if you become pregnant or think you might become pregnant during treatment.

Talk to your healthcare team if you are breastfeeding or plan to breastfeed. It is not known if either treatment passes into your breast milk. Do not breastfeed during treatment with BRAFTOVI and MEKTOVI and for:

    • 2 weeks after the final dose of BRAFTOVI
    • 3 days after the final dose of MEKTOVI

BRAFTOVI may cause fertility problems in males. Talk to your healthcare provider if this is a concern for you.

The most common side effects of BRAFTOVI when taken with MEKTOVI, include: fatigue, nausea, diarrhea, vomiting, abdominal pain, and pain or swelling of your joints.

Before taking BRAFTOVI + MEKTOVI, tell your healthcare provider about all of your medical conditions, including if you:

  • have had bleeding problems
  • have eye problems
  • have heart problems, including a condition called long QT syndrome
  • have been told that you have low blood levels of potassium, calcium, or magnesium
  • have liver or kidney problems
  • have had blood clots
  • have lung or breathing problems
  • have any muscle problems
  • have high blood pressure (hypertension)
  • are pregnant or plan to become pregnant
  • are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over­-the­-counter medicines, vitamins, and herbal supplements. BRAFTOVI and certain other medicines can affect each other, causing side effects or affecting how BRAFTOVI or other medicines work. You should also avoid grapefruit products during treatment with BRAFTOVI.

These are not all the possible side effects of BRAFTOVI and MEKTOVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects related to BRAFTOVI + MEKTOVI products at 1-800-438-1985.

Please see both BRAFTOVI full Prescribing Information, including Medication Guide, and MEKTOVI full Prescribing Information, including Patient Information for additional information.

What is BRAFTOVI + MEKTOVI?

BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) are prescription medicines used together to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body or cannot be removed by surgery, and
  • that has a certain type of abnormal “BRAF” gene

BRAFTOVI should not be used to treat people with wild­type BRAF melanoma. Your healthcare provider will perform a test to make sure that BRAFTOVI + MEKTOVI is right for you.

It is not known if BRAFTOVI or MEKTOVI is safe and effective in children.